Journal
EPIGENOMICS
Volume 12, Issue 11, Pages 935-953Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2019-0352
Keywords
AML; biomarker; circRNAs; CREBRF; hsa_circ_0001947; hsa-miR-329-5p; therapy
Categories
Funding
- National Natural Science Foundation of China [91642110]
- Shandong Provincial Natural Science Foundation [ZR2018PH012]
Ask authors/readers for more resources
Aim: Accumulating evidence has indicated that circular RNAs (circRNAs) are involved in cancer biology. However, their roles in acute myeloid leukemia (AML) remain unclear. Therefore, we aimed to define novel circRNAs involved the development and progression of AML. Materials & methods: We used circRNAs microarray to determine the differential expression profile. Quantitative reverse transcription PCR analyzed the expression of hsa_circ_0001947. The siRNA assesses the function of hsa_circ_0001947in vitro and in vivo. A dual-luciferase and mimics/inhibitor were to determine the target gene relationship. Results:hsa_circ_0001947 functions as a tumor inhibitor to suppress AML cell proliferation through hsa-miR-329-5p/CREBRF axis. Conclusion:hsa_circ_0001947 may be as a novel potential biomarker for the treatment of AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available